Issie Kirby
Stock Analyst at Redburn Atlantic
(0.32)
# 4,026
Out of 4,784 analysts
7
Total ratings
25%
Success rate
-11.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Issie Kirby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Upgrades: Buy | $85 → $115 | $67.74 | +69.77% | 2 | Feb 3, 2025 | |
| ALC Alcon | Upgrades: Neutral | n/a | $95.77 | - | 1 | Oct 10, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Buy | $60 | $19.28 | +211.20% | 1 | May 30, 2024 | |
| PODD Insulet | Initiates: Buy | $235 | $258.75 | -9.18% | 1 | May 30, 2024 | |
| COO The Cooper Companies | Upgrades: Buy | $125 | $83.77 | +49.22% | 2 | Mar 19, 2024 |
DexCom
Feb 3, 2025
Upgrades: Buy
Price Target: $85 → $115
Current: $67.74
Upside: +69.77%
Alcon
Oct 10, 2024
Upgrades: Neutral
Price Target: n/a
Current: $95.77
Upside: -
Tandem Diabetes Care
May 30, 2024
Initiates: Buy
Price Target: $60
Current: $19.28
Upside: +211.20%
Insulet
May 30, 2024
Initiates: Buy
Price Target: $235
Current: $258.75
Upside: -9.18%
The Cooper Companies
Mar 19, 2024
Upgrades: Buy
Price Target: $125
Current: $83.77
Upside: +49.22%